NCT03431610View on ClinicalTrials.gov

A Phase 1b Study Assessing the PK, PD, Safety & Tolerability of SB414 in Atopic Dermatitis

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 13, 2017

Primary Completion Date

May 11, 2018

Study Completion Date

May 11, 2018

Conditions
Atopic Dermatitis
Interventions
DRUG

SB414 2%

Twice daily

DRUG

SB414 6%

Twice daily

DRUG

Vehicle

Placebo comparator

Trial Locations (9)

18201

Novella Site# 265, Hazleton

23502

Novella Site# 114, Norfolk

33134

Novella Site# 242, Coral Gables

33172

Novella Site# 264, Sweetwater

46256

Novella Site# 251, Indianapolis

78660

Novells Site# 263, Pflugerville

83704

Novella Site# 247, Boise

97210

Novella Site# 250, Portland

08009

Novella Site# 201, Berlin

Sponsors

Collaborators (1)

Novella Clinical
All Listed Sponsors
collaborator

Novella Clinical

OTHER

lead

Novan, Inc.

INDUSTRY

NCT03431610 - A Phase 1b Study Assessing the PK, PD, Safety & Tolerability of SB414 in Atopic Dermatitis | Biotech Hunter | Biotech Hunter